Dementia and treatment with L‐dopa in Parkinson's disease
Identifieur interne : 006550 ( Main/Exploration ); précédent : 006549; suivant : 006551Dementia and treatment with L‐dopa in Parkinson's disease
Auteurs : M. Hietanen [Finlande] ; Teräväinen [Finlande]Source :
- Movement Disorders [ 0885-3185 ] ; 1988.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adult, Age Factors, Aged, Aged, 80 and over, Antiparkinson agent, Chemotherapy, Cognition, Cognition (drug effects), Dementia, Dementia (chemically induced), Dopa, Human, Humans, Levodopa (adverse effects), Long term, L‐Dopa, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Parkinson disease, Parkinson's disease, Psychomotor Performance (drug effects), Time Factors, Treatment.
- MESH :
- chemical , adverse effects : Levodopa.
- chemically induced : Dementia.
- drug effects : Cognition, Psychomotor Performance.
- drug therapy : Parkinson Disease.
- psychology : Parkinson Disease.
- Adult, Age Factors, Aged, Aged, 80 and over, Humans, Middle Aged, Time Factors.
Abstract
We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L‐dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who were older at onset of the disease (mean, 62.1 years). There were no significant differences in cognitive and memory functions between the L‐Dopa‐treated and untreated young patients, whereas the L‐Dopa‐treated patients in the older age group performed more poorly than untreated patients in some memory tests (Wechsler Memory Scale I: logical and visula) and cognitive functions (Wechsler Adult Intelligence Scale: similarities, block design, and cognitive flexibility). Treatment duration, disease duration, and mean L‐Dopa dose were comparable for the two age groups. After linear effects of age and disease duration had been eliminated, the duration of L‐Dopa treatment did not correlate with the cognitive vaiables studied. These observations suggest that treatment with L‐Dopa may not be the cause of cognitive impairment in Parkinson's disease.
Url:
DOI: 10.1002/mds.870030311
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E64
- to stream Istex, to step Curation: 001E64
- to stream Istex, to step Checkpoint: 004550
- to stream PubMed, to step Corpus: 005026
- to stream PubMed, to step Curation: 005026
- to stream PubMed, to step Checkpoint: 005037
- to stream Ncbi, to step Merge: 004605
- to stream Ncbi, to step Curation: 004605
- to stream Ncbi, to step Checkpoint: 004605
- to stream Main, to step Merge: 009919
- to stream PascalFrancis, to step Corpus: 003A49
- to stream PascalFrancis, to step Curation: 002D76
- to stream PascalFrancis, to step Checkpoint: 003A50
- to stream Main, to step Merge: 009964
- to stream Main, to step Curation: 006550
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dementia and treatment with L‐dopa in Parkinson's disease</title><author><name sortKey="Hietanen, M" sort="Hietanen, M" uniqKey="Hietanen M" first="M." last="Hietanen">M. Hietanen</name></author><author><name sortKey="Ter V Inen" sort="Ter V Inen" uniqKey="Ter V Inen" last="Ter V Inen">Teräväinen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A4A48390D0732DC458BA1F90BBEBA5AB8976B403</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1002/mds.870030311</idno><idno type="url">https://api.istex.fr/document/A4A48390D0732DC458BA1F90BBEBA5AB8976B403/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001E64</idno><idno type="wicri:Area/Istex/Curation">001E64</idno><idno type="wicri:Area/Istex/Checkpoint">004550</idno><idno type="wicri:doubleKey">0885-3185:1988:Hietanen M:dementia:and:treatment</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:3193964</idno><idno type="wicri:Area/PubMed/Corpus">005026</idno><idno type="wicri:Area/PubMed/Curation">005026</idno><idno type="wicri:Area/PubMed/Checkpoint">005037</idno><idno type="wicri:Area/Ncbi/Merge">004605</idno><idno type="wicri:Area/Ncbi/Curation">004605</idno><idno type="wicri:Area/Ncbi/Checkpoint">004605</idno><idno type="wicri:doubleKey">0885-3185:1988:Hietanen M:dementia:and:treatment</idno><idno type="wicri:Area/Main/Merge">009919</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:89-0292966</idno><idno type="wicri:Area/PascalFrancis/Corpus">003A49</idno><idno type="wicri:Area/PascalFrancis/Curation">002D76</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">003A50</idno><idno type="wicri:doubleKey">0885-3185:1988:Hietanen M:dementia:and:treatment</idno><idno type="wicri:Area/Main/Merge">009964</idno><idno type="wicri:Area/Main/Curation">006550</idno><idno type="wicri:Area/Main/Exploration">006550</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dementia and treatment with L‐dopa in Parkinson's disease</title><author><name sortKey="Hietanen, M" sort="Hietanen, M" uniqKey="Hietanen M" first="M." last="Hietanen">M. Hietanen</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Departments of General Psychology, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Ter V Inen" sort="Ter V Inen" uniqKey="Ter V Inen" last="Ter V Inen">Teräväinen</name><affiliation wicri:level="4"><country xml:lang="fr">Finlande</country><wicri:regionArea>Departments of Neurology, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1988">1988</date><biblScope unit="vol">3</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="263">263</biblScope><biblScope unit="page" to="270">270</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A4A48390D0732DC458BA1F90BBEBA5AB8976B403</idno><idno type="DOI">10.1002/mds.870030311</idno><idno type="ArticleID">MDS870030311</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Antiparkinson agent</term><term>Chemotherapy</term><term>Cognition</term><term>Cognition (drug effects)</term><term>Dementia</term><term>Dementia (chemically induced)</term><term>Dopa</term><term>Human</term><term>Humans</term><term>Levodopa (adverse effects)</term><term>Long term</term><term>L‐Dopa</term><term>Middle Aged</term><term>Nervous system diseases</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Parkinson disease</term><term>Parkinson's disease</term><term>Psychomotor Performance (drug effects)</term><term>Time Factors</term><term>Treatment</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Dementia</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Cognition</term><term>Psychomotor Performance</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Age Factors</term><term>Aged</term><term>Aged, 80 and over</term><term>Humans</term><term>Middle Aged</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiparkinsonien</term><term>Chimiothérapie</term><term>Cognition</term><term>Dopa</term><term>Homme</term><term>Long terme</term><term>Parkinson maladie</term><term>Système nerveux pathologie</term><term>Traitement</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the neuropsychological performance of patients with Parkinson's disease who were young at onset of the disease (mean age, 41.4 years) and had received prolonged L‐dopa treatment (mean, 52.1 months) with nontreated patients of the same age. A similar comparison was made for patients who were older at onset of the disease (mean, 62.1 years). There were no significant differences in cognitive and memory functions between the L‐Dopa‐treated and untreated young patients, whereas the L‐Dopa‐treated patients in the older age group performed more poorly than untreated patients in some memory tests (Wechsler Memory Scale I: logical and visula) and cognitive functions (Wechsler Adult Intelligence Scale: similarities, block design, and cognitive flexibility). Treatment duration, disease duration, and mean L‐Dopa dose were comparable for the two age groups. After linear effects of age and disease duration had been eliminated, the duration of L‐Dopa treatment did not correlate with the cognitive vaiables studied. These observations suggest that treatment with L‐Dopa may not be the cause of cognitive impairment in Parkinson's disease.</div></front></TEI><affiliations><list><country><li>Finlande</li></country><region><li>Uusimaa</li></region><settlement><li>Helsinki</li></settlement><orgName><li>Université d'Helsinki</li></orgName></list><tree><country name="Finlande"><region name="Uusimaa"><name sortKey="Hietanen, M" sort="Hietanen, M" uniqKey="Hietanen M" first="M." last="Hietanen">M. Hietanen</name></region><name sortKey="Ter V Inen" sort="Ter V Inen" uniqKey="Ter V Inen" last="Ter V Inen">Teräväinen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006550 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006550 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:A4A48390D0732DC458BA1F90BBEBA5AB8976B403
|texte= Dementia and treatment with L‐dopa in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |